Trans-3,4-dimethylthiane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻烷
• 英文名称: Trans-3,4-dimethylthiane
• 英文别名: 3,4-dimethylthiane
• 化学式: C₇H₁₄S
• 分子量: 130.25
• InChiKey: JLSMLKZFQHSQRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] INHIBITORS OF HEPATITIS C VIRUS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：GILEAD SCIENCES INC

  公开号：WO2014008285A1

  公开（公告）日：2014-01-09

  Compounds of Formula I are disclosed, As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

  化合物I的结构已经披露，以及其药用盐。还披露了使用这些化合物的方法和含有这些化合物的药物组合物。
• Inhibitors of Checkpoint Kinases
  申请人：Brnardic Edward J.

  公开号：US20080114016A1

  公开（公告）日：2008-05-15

  The instant invention provides for compounds which comprise fused pyrazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by ad-ministering the compound to a patient in need of treatment of cancer.

  本发明提供了一种含有融合嘧唑的化合物，可以抑制CHK1活性。本发明还提供了包含这些抑制化合物的组合物以及通过向需要癌症治疗的患者施用该化合物来抑制CHK1活性的方法。
• N-Heterocyclic derivatives as nos inhibitors
  申请人：Berlex, Inc.

  公开号：EP1754703A2

  公开（公告）日：2007-02-21

  N-Heterocyclic derivatives of formula (I) are described herein, as well as other N-Heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.

  本文描述了作为一氧化氮合酶抑制剂的式 (I) N-杂环衍生物以及其他 N-杂环。本文还描述了含有这些化合物的药物组合物、使用这些化合物作为一氧化氮合酶抑制剂的方法以及合成这些化合物的工艺。
• INHIBITORS OF HEPATITIS C VIRUS
  申请人：Gilead Sciences, Inc.

  公开号：EP3159345A1

  公开（公告）日：2017-04-26

  Compounds of Formula (IV), as well as pharmaceutically acceptable salts thereof, are disclosed: The compounds are useful in the treatment of Hepatitis C infections.

  本研究公开了式（IV）化合物及其药学上可接受的盐类： 这些化合物可用于治疗丙型肝炎感染。
• Substituted bicyclic compounds as bromodomain inhibitors
  申请人：ZENITH EPIGENETICS LTD.

  公开号：US10166215B2

  公开（公告）日：2019-01-01

  The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.

  本发明涉及取代的双环化合物，这些化合物可通过与溴结构域结合来抑制 BET 蛋白的功能；本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在治疗中的应用。

表征谱图